Production & Sales

EIB launches €50m Africa pharmaceutical manufacturing initiative

The European Investment Bank launched the first ever scheme to strengthen local production of Active Pharmaceutical Ingredients in Africa and scale up drug manufacturing essential to improve public health.

Moderna confirms agreement with Singapore for supply of mRNA vaccine against Covid-19

Moderna confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.

Thermo Fisher Scientific further expands global footprint for drug product development and commercial manufacturing

Thermo Fisher Scientific, the world leader in serving science, announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.

BioCryst announces $325m of funding from Royalty Pharma and Athyrium Capital Management

BioCryst Pharmaceuticals, Royalty Pharma, and Athyrium Capital Management, announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930.

Piramal Pharma Solutions invests $32m to expand Riverview Michigan facility

Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO) announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).

Eli Lilly announces 650,000 additional doses of bamlanivimab purchased by US government to treat Covid-19

The US government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021, with at least 350,000 of the additional doses delivered in December 2020.

Boston Scientific signs agreement to divest BTG Specialty Pharmaceuticals business

Boston Scientific announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.

SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185

SAB Biotherapeutics (SAB) as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.

Dr. Reddy’s to acquire select anti-allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan

Dr. Reddy’s Laboratories has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned.